Paper329987
Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate).
Dyke RW and 1 other. Cancer Treat Rev, 1977. Cited by 102 papers, by iCite.
Cite this record
ConductScience Library. Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate). Papers, record 329987. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/329987
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Vinblastine | Major topic |
| Animals | |
| Clinical Trials as Topic | |
| Female | |
| Humans | |
| Kinetics | |
| Male | |
| Melanoma | |
| Neoplasms, Experimental | |
| Vincristine |
Source PubMed
Cited by22
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 102 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 8306418 | Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as determined by high-performance liquid chromatography. | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/8306418 | PubMed |
| 8262726 | Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography. | Invest New Drugs | 1993 | https://conductscience.org/library/papers/8262726 | PubMed |
| 8262725 | Is there a role for vindesine in the treatment of non-small cell lung cancer? | Invest New Drugs | 1993 | https://conductscience.org/library/papers/8262725 | PubMed |
| 7460196 | Phase I evaluation of divided-dose vinblastine sulfate. | Cancer Chemother Pharmacol | 1980 | https://conductscience.org/library/papers/7460196 | PubMed |
| 7326201 | Biochemical effects of vindesine. | Br J Cancer | 1981 | https://conductscience.org/library/papers/7326201 | PubMed |
| 7307235 | Neurological toxicity of vindesine used in combination chemotherapy of 51 human solid tumors. | Cancer Chemother Pharmacol | 1981 | https://conductscience.org/library/papers/7307235 | PubMed |
| 7296754 | Experimental in vivo cross-resistance of vinca alkaloid drugs. | Cancer Chemother Pharmacol | 1981 | https://conductscience.org/library/papers/7296754 | PubMed |
| 6678881 | Vindesine in head and neck cancer. A Southwest Oncology Group Phase II pilot study. | Invest New Drugs | 1983 | https://conductscience.org/library/papers/6678881 | PubMed |
| 6381742 | Cancer chemotherapy: past, present, and future--Part I. | J Natl Med Assoc | 1984 | https://conductscience.org/library/papers/6381742 | PubMed |
| 4041363 | Cytotoxicity of etretinate and vindesine. | Br J Cancer | 1985 | https://conductscience.org/library/papers/4041363 | PubMed |
| 3390658 | Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine. | Br J Pharmacol | 1988 | https://conductscience.org/library/papers/3390658 | PubMed |
| 2384117 | In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. I. Vindesine (4-deacetyl-vinblastine 3-carboxyamide). | Eur J Drug Metab Pharmacokinet | 1990 | https://conductscience.org/library/papers/2384117 | PubMed |
| 2254384 | Long-term application of vindesine: toxicity and tolerance. | J Cancer Res Clin Oncol | 1990 | https://conductscience.org/library/papers/2254384 | PubMed |
| 2191847 | Antineoplastic drugs in 1990. A review (Part II). | Drugs | 1990 | https://conductscience.org/library/papers/2191847 | PubMed |
| 455587 | Vindesine. A review of phase-II trials. | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/455587 | PubMed |
| 455586 | Phase II evaluation of vindesine in the treatment of colorectal and esophageal tumors. | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/455586 | PubMed |
| 455585 | Vindesine in the treatment of breast cancer. | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/455585 | PubMed |
| 455584 | Vindesine as a single agent in the treatment of advanced malignant melanoma. | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/455584 | PubMed |
| 455583 | Clinical pharmacokinetics of vindesine. | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/455583 | PubMed |
| 455582 | Correlation of the clinical neurotoxicity of the vinca alkaloids vincristine, vinblastine, and vindesine with their effects on cultured rat midbrain cells. | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/455582 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/329987
GET https://conductscience.org/api/papers/v1/329987/cited_by?page=2